更年期激素治疗黑框警告的取消
本文回顾美国FDA于2003年基于WHI口服结合雌激素与醋酸甲羟孕酮研究的部分数据,对更年期激素治疗(MHT)产品施加黑框警告的历史。
要点
- 黑框警告曾将WHI研究结论不当推广至所有剂量、剂型与给药途径。
- 新标签取消「最低有效剂量、最短疗程」的强制要求,并纳入启动时机指导。
核心结论
- FDA取消MHT黑框警告,转向产品特异性标签与个体化获益-风险评估,支持共享决策。
研究设计与样本
- 本文为发表于Obstet Gynecol的综述/评论,回顾FDA黑框警告的由来与取消依据,未报告原始研究样本。
主要发现
- 2003年FDA基于WHI口服结合雌激素与醋酸甲羟孕酮研究,对MHT产品施加黑框警告,但该警告被不当推广至所有剂量、剂型与给药途径,包括局部阴道治疗。
- 取消决定基于FDA对科学文献的独立全面审查、2025年7月17日专家小组的讨论及60天公众评议期。
关键数值与推荐
- FDA转向产品特异性标签,取消「最低有效剂量、最短疗程」的强制要求。
- 标签纳入在绝经10年内或60岁前启动MHT的时机指导。
临床怎么用
- 临床应以准确数据替代误导信息,开展个体化获益-风险评估并与患者共享决策。
- 结合现代风险评估与最新临床证据,为每位患者优化MHT使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In 2003, the U.S. Food and Drug Administration (FDA) issued a black box warning on menopausal hormone therapy (MHT) products based on putative harm of secondary outcomes and incompletely collected and adjudicated data from the Women's Health Initiative (WHI) oral conjugated equine estrogens and medroxyprogesterone acetate study. Despite the specific parameters and limitations of the WHI study, these warnings were inappropriately generalized across all doses, formulations, and routes of administration, including local vaginal therapies, under the mandate to prescribe the "lowest effective dose for the shortest duration." After 22 years of clinical controversy, the U.S. Department of Health and Human Services and the FDA announced removal of the boxed warning on November 10, 2025. This decision was based on the FDA's independent and comprehensive review of the scientific literature, deliberations from an expert panel on July 17, 2025, and a 60-day public comment period. The FDA's transition to product-specific labeling, the removal of the mandate for the lowest effective dose for the shortest duration, and the inclusion of guidance on the optimal timing of MHT initiation within 10 years of menopause or before age 60 years, represent critical steps toward evidence-based menopause management. By replacing misleading information with accurate data, this regulatory shift facilitates individualized benefit-risk assessments and empowers shared decision making. Ultimately, these updates ensure that MHT use is optimized for the specific needs of each patient, integrating modern risk assessment with the latest clinical evidence to improve long-term health outcomes.
引用
- Sriprasert I, Hodis HN, Mack WJ, et al. Elimination of the Black Box Warning on Menopausal Hormone Therapy. Obstet Gynecol. 2026. PMID: 41687116. doi:10.1097/AOG.0000000000006226
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。